Advertisement ANI Pharmaceuticals introduces Propafenone tablets to treat several arrhythmias - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ANI Pharmaceuticals introduces Propafenone tablets to treat several arrhythmias

US-based ANI Pharmaceuticals has launched Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, for the treatment of various arrhythmias.

Propafenone is indicated to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease.

Additionally, it is indicated to prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) related with disabling symptoms in these patients.

According to IMS Health, the overall US market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14m in 2014.

ANI Pharmaceuticals president and chief executive officer Arthur Przybyl said: "We are pleased to announce the launch of our fourth product from the portfolio of approved generic products we acquired from Teva in January 2014."

The drug is also indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life threatening.

The company is focused on developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Currently, the company is focused on areas of product development including narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.